Physician profile
Jenna Flick
NPI 1295466373
$3,153.52
in general payments reported to CMS, 2019-2025
19 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.75 · 2023: $863 · 2024: $996 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.82 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $700.33 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $406.32 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $366.46 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.49 | 2022-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $265.32 | 2024-2025 | Vowst |
| Pfizer INC. | $248.50 | 2024-2025 | |
| Madrigal Pharmaceuticals | $151.88 | 2024 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $132.34 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $129.80 | 2023 | |
| Lilly USA, LLC | $60.37 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $54.71 | 2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $50.50 | 2023 | |
| Celgene Corporation | $44.66 | 2023 | Zeposia |
| Qol Medical, LLC | $42.54 | 2023-2024 | Sucraid, Sucraid |
| Novo Nordisk INC | $34.95 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $34.92 | 2023-2024 | Hyrimoz |
| Ardelyx, INC. | $31.17 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $30.56 | 2024 | Rebyota |
| Celltrion USA INC. | $16.70 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Flick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.